| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/18/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
| 06/16/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
| 03/24/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | → Buy |
| 11/15/2022 | 203.03% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 09/16/2022 | 304.04% | Citigroup | $16 → $12 | Maintains | Buy |
| 08/02/2022 | 236.7% | SVB Leerink | $11 → $10 | Maintains | Outperform |
| 05/11/2022 | 270.37% | SVB Leerink | $10 → $11 | Maintains | Outperform |
| 09/17/2021 | 203.03% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 09/03/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/02/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 03/19/2021 | 135.69% | SVB Leerink | $5 → $7 | Maintains | Market Perform |
| 12/15/2020 | 68.35% | SVB Leerink | $7 → $5 | Downgrades | Outperform → Market Perform |
| 12/14/2020 | 287.21% | HC Wainwright & Co. | $13 → $11.5 | Maintains | Buy |
| 11/24/2020 | 59.93% | Goldman Sachs | → $4.75 | Initiates Coverage On | → Neutral |
| 09/09/2020 | 135.69% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 05/14/2020 | 203.03% | SVB Leerink | $10 → $9 | Maintains | Outperform |
What is the target price for Innate Pharma (IPHA)?
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 287.21% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Innate Pharma (IPHA)?
The latest analyst rating for Innate Pharma (NASDAQ: IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
Is the Analyst Rating Innate Pharma (IPHA) correct?
While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $0.00 to $11.50. The current price Innate Pharma (IPHA) is trading at is $2.97, which is within the analyst's predicted range.